Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome
Fetal valproate syndrome (FVS) is caused by in utero exposure to the drug sodium valproate. Valproate is used worldwide for the treatment of epilepsy, as a mood stabiliser and for its pain-relieving properties. In addition to birth defects, FVS is associated with an increased risk of autism spectrum...
Main Authors: | John Jacob, Vanessa Ribes, Steven Moore, Sean C. Constable, Noriaki Sasai, Sebastian S. Gerety, Darren J. Martin, Chris P. Sergeant, David G. Wilkinson, James Briscoe |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2014-01-01
|
Series: | Disease Models & Mechanisms |
Subjects: | |
Online Access: | http://dmm.biologists.org/content/7/1/107 |
Similar Items
-
Function of Proneural Genes Ascl1 and Asense in Neurogenesis: How Similar Are They?
by: Diogo S. Soares, et al.
Published: (2022-02-01) -
Ascl1 phospho-site mutations enhance neuronal conversion of adult cortical astrocytes in vivo
by: Hussein Ghazale, et al.
Published: (2022-08-01) -
Direct Reprogramming of Adult Human Somatic Stem Cells Into Functional Neurons Using Sox2, Ascl1, and Neurog2
by: Jessica Alves de Medeiros Araújo, et al.
Published: (2018-06-01) -
Effects of Pre-pregnancy Chronic Valproate Administration in Female Rats on Avoidance Memory and Hippocampal Gene Expression of Offspring
by: Masoumeh Gholami, et al.
Published: (2020-02-01) -
Chromatin Imbalance as the Vertex Between Fetal Valproate Syndrome and Chromatinopathies
by: Chiara Parodi, et al.
Published: (2021-04-01)